-transparent.png){kind=logo}
The pharmacokinetic parameters of etoposide were established in 35 patients receiving the drug parenterally within the framework of different polychemotherapy protocols. A total of 62 data for 24-h kinetics were analysed. After sample extraction and high-performance liquid chromatography (HPLC) or thin-layer chromatographic (TLC) separation, etoposide was measured by means of [252Cf]-plasma desorption mass spectrometry (PDMS). This highly specific detection system proved to be very practicable and reproducible. The present study comprised two parts that were absolutely comparable in terms of clinical and pharmacokinetic parameters. In part II of the study, sensitivity was improved by modifying the analytical technique. After the exclusion of patients who had previously been given cisplatin or who exhibited renal impairment and of one patient who showed extremely high levels of alkaline phosphatase, gamma-GT and SGPT, the mean values calculated for the pharmacokinetic parameters evaluated were: beta-elimination half-life (t 1/2 beta), 4.9 +/- 1.2 h; mean residence time (MRT), 6.7 +/- 1.4 h; area under the concentration-time curve (AUC), 5.43 +/- 1.74 mg min ml-1; volume of distribution at steady state (Vdss), 6.8 +/- 2.7 l/m2; and clearance (Cl), 18.8 +/- 5.3 ml min-1 m-2. The pharmacokinetic parameters were correlated with 12 different demographic or biochemical conditions. Impaired renal function, previous application of cisplatin and the age of patients were found to influence etoposide disposition to a statistically significant extent. We suggest that the dose of etoposide should be reduced in elderly patients and/or in individuals with impaired renal function, especially in those exhibiting general risk factors such as reduced liver function with regard to the polychemotherapy.
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
January 1987,
Cancer chemotherapy and pharmacology,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
August 1982,
European journal of cancer & clinical oncology,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
July 1997,
Bulletin du cancer,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
January 1991,
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
December 1984,
Naunyn-Schmiedeberg's archives of pharmacology,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
August 1996,
Journal of pharmacokinetics and biopharmaceutics,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
November 1993,
The Annals of pharmacotherapy,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
January 1994,
Cancer chemotherapy and pharmacology,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
June 1991,
Journal of pharmaceutical sciences,
K H Pflüger, and
M Hahn, and
J B Holz, and
L Schmidt, and
P Köhl, and
H W Fritsch, and
H Jungclas, and
K Havemann
January 2000,
Chemotherapy,
